U.S. Markets open in 3 hrs 39 mins
  • S&P Futures

    4,464.33
    -9.92 (-0.22%)
     
  • Dow Futures

    34,696.80
    -52.20 (-0.15%)
     
  • Nasdaq Futures

    15,486.67
    -31.08 (-0.20%)
     
  • Russell 2000 Futures

    2,241.04
    +7.84 (+0.35%)
     
  • Crude Oil

    70.55
    -1.42 (-1.97%)
     
  • Gold

    1,758.90
    +7.50 (+0.43%)
     
  • Silver

    22.38
    +0.08 (+0.36%)
     
  • EUR/USD

    1.1707
    -0.0025 (-0.2107%)
     
  • 10-Yr Bond

    1.3700
    0.0000 (0.00%)
     
  • Vix

    25.39
    +6.70 (+35.85%)
     
  • GBP/USD

    1.3662
    -0.0075 (-0.5465%)
     
  • USD/JPY

    109.6300
    -0.2650 (-0.2411%)
     
  • BTC-USD

    44,937.35
    -3,172.95 (-6.60%)
     
  • CMC Crypto 200

    1,122.10
    -103.43 (-8.44%)
     
  • FTSE 100

    6,850.93
    -112.71 (-1.62%)
     
  • Nikkei 225

    30,500.05
    +176.75 (+0.58%)
     

TALIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Talis on Behalf of Talis Stockholders and Encourages Investors to Contact the Firm

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, September 13, 2021--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Talis Biomedical Corporation ("Talis" or the "Company") (NASDAQ: TLIS) on behalf of Talis stockholders. Our investigation concerns whether Talis has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On August 10, 2021, Talis reported its second quarter 2021 financial results. During the related conference call, the Company revealed that its "development timelines have been extended by delays in the launching of [Talis’] COVID-19 test and manufacturing scale."

On this news, the Company’s stock price fell $0.58, or 6%, to close at $8.39 per share on August 11, 2021, thereby injuring investors.

Then, on August 30, 2021, after the market closed, Talis announced that its Chief Executive Officer, Brian Coe, had "stepped down."

On this news, the Company’s stock price fell $1.00, or 11%, to close at $8.06 per share on August 31, 2021, thereby injuring investors further.

If you purchased or otherwise acquired Talis shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210913005888/en/

Contacts

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com